Clinical Trials Logo

Clinical Trial Summary

The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in participants with chronic rhinosinusitis with nasal polyps (CRSwNP) and to assess the safety and tolerability of verekitug (UPB-101) compared to placebo.


Clinical Trial Description

This is a multicenter, randomized, placebo controlled, parallel group study to assess the efficacy and safety of verekitug (UPB-101) administered subcutaneously (SC) in participants with CRSwNP on background therapy with stable dosage of intranasal corticosteroids (INCS). Approximately 70 participants will be randomized. Participants will receive verekitug (UPB-101) or placebo over a 24-week treatment period. In addition, this study consists of a 3 to 5-week Screening Period and a 4-week Follow-up Period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06164704
Study type Interventional
Source Upstream Bio Inc.
Contact Upstream Bio Clinical Trials Information (Privacy Notice: https:
Phone 888-446-3130
Email clinicaltrials@upstreambio.com
Status Recruiting
Phase Phase 2
Start date December 18, 2023
Completion date April 2025

See also
  Status Clinical Trial Phase
Recruiting NCT05895929 - The Role of IL5 in Epithelial Cell Integrity Early Phase 1
Recruiting NCT05891483 - Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Recruiting NCT04998604 - EValuating trEatment RESponses of Dupilumab Versus Omalizumab in Type 2 Patients Phase 4
Recruiting NCT06069310 - Mepolizumab Effectiveness in Patients With Chronic Rhinosinusitis, Nasal Polyps and Comorbid Severe Eosinophilic Asthma
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Active, not recruiting NCT05529784 - Dupilumab in the Treatment of Severe Uncontrolled CRSwNP: a Multicentre Observational Real-life Study (DUPIREAL)
Recruiting NCT05902325 - Identifying Predictors Of Response To Mepolizumab In CRSwNP Phase 4
Completed NCT05049122 - Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52) Phase 4
Not yet recruiting NCT05598411 - CST1-Guided Oral Glucocorticoids Management for CRSwNP Phase 4
Active, not recruiting NCT05553951 - Adherence in Global Airways N/A
Recruiting NCT05131464 - The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps Phase 2
Recruiting NCT05598424 - CST1 Predictive Model of Oral Glucocorticoid Therapy Sensitivity for Chronic Rhinosinusitis With Polyps Phase 4
Active, not recruiting NCT05649813 - A Study in Male and Female Adult Participants With Chronic Rhinosinusitis With Nasal Polyps In the Greater Gulf Region
Recruiting NCT04628442 - Tissue Immune Interaction in Nasal Polyposis
Active, not recruiting NCT06118554 - 3D Printing to Improve Nasal Irrigation Outcome N/A
Active, not recruiting NCT04596189 - Dupilumab for Prevention of Recurrence of CRSwNP After ESS Phase 4
Recruiting NCT02668861 - Effect of Oral Vitamin D3 on Chronic Rhinosinusitis Treatment in Adults With Lower Vitamin D Levels Phase 3
Active, not recruiting NCT05878093 - Dupilumab in Chinese Adult Participants With CRSwNP Phase 3
Completed NCT05931744 - The Role of Budesonide Intrapolyp Injection in the Management of Type 2 Chronic Rhinosinusitis Phase 2/Phase 3
Recruiting NCT05938972 - Real Life Study of Biologicals in Patients With Severe CRSwNP